Fabian Gonell

Fabian Gonell is Senior Vice President, Licensing Strategy and Legal Counsel of Qualcomm’s Technology Licensing division, where his responsibilities include developing the Company’s licensing strategy, negotiating license agreements, and overseeing the company’s compliance with the rules of standards organizations. He has played a major role in structuring and negotiating license agreements with many of Qualcomm’s licensees, including Apple, Samsung, LGE, Ericsson, and Nokia/Microsoft, as well as in Qualcomm’s response to regulatory investigations of Qualcomm’s licensing practices.

Prior to joining Qualcomm, Mr. Gonell was a litigator at Cravath, Swaine & Moore LLP in New York, where he represented Qualcomm and other clients in patent and antitrust litigation. He also served as an adjunct professor at the Fordham University School of Law, where he taught courses in interviewing, counseling and negotiation. Mr. Gonell holds a BA in Economics from the City University of New York and a JD from the Fordham University School of Law, where he was Editor-in-Chief of the Fordham Law Review.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More